Method for treating a pulmonary hypertension condition
A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
1. A method for treating a human patient exhibiting a pulmonary arterial hypertension (PAH) of WHO Class IV at baseline, comprising orally administering to the patient a therapeutically effective amount of ambrisentan.
2. The method of claim 1 , wherein the PAH is further associated with a connective tissue disease (CTD).
3. The method of claim 1 , wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg.
4. The method of claim 3 , wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg.
5. The method of claim 4 , wherein the administration continues for 12 weeks.
6. The method of claim 1 , wherein the administration is initiated within 2 years following diagnosis of the PAH condition.